The Phase 3 INDIGO Trial was presented in the 2023 ASCO Presidential Plenary session. Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A ...

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 ...

The FDA and EMA are reviewing data from the phase 3 INDIGO study, which tested vorasidenib as a monotherapy for patients with residual or recurrent IDH mutant low-grade glioma who have previously ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test. Currently, TIBSOVO is approved for the treatment of newly diagnosed acute myeloid ...